Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Short-term Investments (2016 - 2019)

Macrogenics (MGNX) has disclosed Short-term Investments for 5 consecutive years, with $89.3 million as the latest value for Q4 2019.

  • On a quarterly basis, Short-term Investments rose 601.09% to $89.3 million in Q4 2019 year-over-year; TTM through Dec 2019 was $89.3 million, a 601.09% increase, with the full-year FY2019 number at $89.3 million, up 601.09% from a year prior.
  • Short-term Investments was $89.3 million for Q4 2019 at Macrogenics, up from $12.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $192.9 million in Q4 2016 to a low of $12.7 million in Q4 2018.
  • A 5-year average of $106.2 million and a median of $93.4 million in 2017 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: plummeted 86.36% in 2018, then soared 601.09% in 2019.
  • Macrogenics' Short-term Investments stood at $142.9 million in 2015, then skyrocketed by 35.01% to $192.9 million in 2016, then tumbled by 51.58% to $93.4 million in 2017, then tumbled by 86.36% to $12.7 million in 2018, then skyrocketed by 601.09% to $89.3 million in 2019.
  • Per Business Quant, the three most recent readings for MGNX's Short-term Investments are $89.3 million (Q4 2019), $12.7 million (Q4 2018), and $93.4 million (Q4 2017).